RayKnowChina Research Map
Shortlist0

RecruitingStomach cancerN/A

Registered title, quoted from ClinicalTrials.gov

Image-Guided Platform-Assisted Sentinel Lymph Node Retrieval in Early Gastric Cancer

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Beijing Friendship Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorBeijing Friendship Hospital首都医科大学附属北京友谊医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07835087, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. Histologically confirmed gastric adenocarcinoma based on preoperative endoscopic biopsy.

    Inclusion criterion 3

  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and considered able to tolerate surgery and anesthesia.

    Inclusion criterion 2

  4. Pregnancy or breastfeeding.

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07835087, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age between 18 and 80 years, inclusive.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and considered able to tolerate surgery and anesthesia.
  • Histologically confirmed gastric adenocarcinoma based on preoperative endoscopic biopsy.
  • Clinical stage cT1N0M0 based on multidisciplinary evaluation and appropriate preoperative examinations, including endoscopy and imaging, or patients after non-curative endoscopic submucosal dissection (ESD) who are considered appropriate candidates for further surgical treatment.
  • Adequate hepatic, renal, cardiac, pulmonary, and bone marrow function to tolerate the planned surgical and perioperative management.
  • Considered clinically suitable for laparoscopic-endoscopic cooperative surgery combined with sentinel lymph node navigation surgery (LECS-SNNS).
  • Able to understand the study procedures and provide written informed consent voluntarily.

Exclusion Criteria:

  • Patients who meet the absolute indications for endoscopic submucosal dissection according to the applicable Chinese gastric cancer treatment guidelines.
  • Contraindications to the use of the lymphatic tracer or to endoscopic examination.
  • Unable to undergo ESD or failure of ESD treatment.
  • Inability to determine the extent of tracer staining or fluorescence mapping.
  • Contraindications to surgery, including clinically significant coagulation disorders or severe cardiopulmonary dysfunction.
  • Previous gastrointestinal surgery, chemotherapy, or radiotherapy.
  • Preoperative imaging indicating bulky, conglomerated, or markedly enlarged metastatic lymph nodes.
  • Concurrent malignancy involving another organ system, or intraoperative confirmation of metastatic gastric cancer or a non-gastric primary malignancy.
  • Pregnancy or breastfeeding.
  • Psychiatric disorders, cognitive impairment, or other conditions that impair the ability to provide informed consent or comply with study procedures.
  • Any other condition that, in the investigator's judgment, makes the individual unsuitable for participation in the study.

Quoted from ClinicalTrials.gov, NCT07835087, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07835087, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07835087